Blue Biofuels, Inc. (BIOF) director Chris J. Kneppers reported a sale of 100,000 shares of common stock on October 13, 2026, at $0.10 per share. He held 19,872,677 shares after the transaction. A remark states that 18,872,677 shares are held jointly with Angela Kneppers. No Rule 10b5-1 plan is reported.
Blue Biofuels, Inc. director Chris Kneppers reported a proposed sale of 908,355 common shares, with an approximate sale date of October 15, 2026. Raymond James is listed as broker, and the proposed sale has an aggregate market value of $90,835.50. Blue Biofuels lists 324,168,980 shares outstanding. Kneppers acquired the shares from Blue Biofuels in a private placement on December 16, 2019, for cash.
BLUE BIOFUELS, INC. (BIOF) director Chris J Kneppers reported two open-market sales of common stock. On September 4, 2026, he sold 200,000 shares at $0.10 per share, followed by a sale of 300,000 shares at $0.10 per share on September 8, 2026. No Rule 10b5-1 trading plan is reported. A remark states that 18,972,677 shares are held jointly with Angela Kneppers.
BLUE BIOFUELS, INC. (BIOF) director Chris J. Kneppers reported selling a total of 1,000,000 shares of Common Stock in three open-market or private transactions from September 1 to September 3, 2026, at prices between $0.09 and $0.10 per share. A remark states that 19,472,677 shares are held jointly with Angela Kneppers, indicating a substantial remaining joint position. No transactions are reported as made under a Rule 10b5-1 trading plan.
BLUE BIOFUELS, INC. (BIOF) has a notice of proposed sale under Rule 144 filed for the account of director Chris Kneppers. The notice covers up to 1,500,000 shares of common stock, with an aggregate market value of $150,000, to be sold through Raymond James on the OTCQB on or after September 3, 2026.
The shares relate to securities acquired from Blue Biofuels, Inc. in a private placement on May 9, 2022, paid for in cash on May 2, 2022. The filing lists 324,168,980 shares of this class outstanding. No sales during the past three months are disclosed.
Blue Biofuels, Inc. is a development-stage renewable fuels technology company focused on its Cellulose-to-Sugar (CTS) process and related biofuel pathways. It has not generated material revenue and remains pre-commercial.
For the six months ended June 30, 2026, the company reported a net loss of $1,414,596 and accumulated deficit of $61,544,958. Operating cash outflow was $687,359. Cash and cash equivalents were only $22,040 at June 30, 2026, with a working capital deficit of $3,341,277 and stockholders’ deficit of $4,058,672. Management states that these conditions, along with continued expected losses, raise substantial doubt about its ability to continue as a going concern.
Total liabilities were $5,379,631, including significant related-party obligations: $2,859,070 of deferred wages and directors’ fees and $1,345,000 of related-party notes, plus related-party and third-party convertible notes. During the first half of 2026, the company raised $702,000 through equity, warrant exercises, and notes, and settled $100,630 of legacy notes with shares, while continuing to invest in CTS commercialization and maintaining extensive option and warrant programs for management and directors.
Blue Biofuels, Inc. reported a change in its independent auditor following the merger of Assure CPA, LLC into Sadler, Gibb & Associates, LLC. As a result of this transaction, Assure CPA ceased public accounting operations and resigned as the company’s independent registered public accounting firm.
The Audit Committee approved both Assure CPA’s resignation and the engagement of Sadler Gibb as auditor for the fiscal year ending 2026. Assure CPA’s audit reports for 2024 and 2025 contained explanatory paragraphs expressing substantial doubt about Blue Biofuels’ ability to continue as a going concern, but showed no disagreements or reportable events, and Assure CPA provided a confirming letter to the SEC.
Blue Biofuels, Inc. reported another pre-revenue quarter for the three months ended March 31, 2026, as it continues developing its Cellulose-to-Sugar (CTS) and sustainable aviation fuel technologies. The company generated no revenue and posted a net loss of $663,801, versus a loss of $243,833 a year earlier, largely because 2025 included $444,970 of DOE grant income.
Operating expenses were $659,498, with general and administrative costs of $274,585 and research and development of $384,913, reflecting ongoing pilot and commercialization work. Cash used in operations was $418,535, leaving only $8,665 in cash at quarter-end.
Total liabilities were $5,246,366 against total assets of $1,309,640, resulting in a stockholders’ deficit of $3,936,726 and a working capital deficit of $3,098,898. Management disclosed substantial doubt about the company’s ability to continue as a going concern, noting accumulated losses of $60,794,163 and dependence on new financing.
Blue Biofuels, Inc. reported a net loss of $2.87 million for the year ended December 31, 2025, compared with a $1.42 million loss in 2024, and again generated no revenue from its core operations. Results were helped by $865,000 of U.S. Department of Energy grant income, but the company still recorded an accumulated deficit of $60.13 million.
Blue Biofuels advanced its patented Cellulose-to-Sugar (CTS) technology, completed pilot-plant upscaling work, and formed a 50-50 joint venture with Vertimass to target sustainable aviation fuel production in Florida. However, it ended 2025 with only $65,200 in cash, a working capital deficit of $2.91 million, negative equity of $3.71 million, and its auditors highlighted substantial doubt about its ability to continue as a going concern. Management estimates it will need roughly $90 million in project financing to fund its share of the VertiBlue Fuels joint venture and move into commercial production.
Blue Biofuels (BIOF) filed its Q3 2025 10‑Q, reporting no revenue and a net loss of $422,547 for the quarter and $1,587,132 for the nine months ended September 30, 2025. The company recognized $420,030 in DOE grant income in the quarter and $865,000 year‑to‑date, which partially offset operating expenses.
Cash was $95,194 and total liabilities were $4,543,537 as of September 30, 2025. Stockholders’ deficit widened to $3,057,336. Management disclosed “substantial doubt” about the company’s ability to continue as a going concern due to recurring losses, limited liquidity, and the need for additional financing.
During 2025 to date, the company raised cash through equity and debt: $435,000 from private placements of common stock and warrants, $185,000 of related‑party notes, and $6,250 from warrant exercises. Shares outstanding were 315,723,332 as of October 23, 2025; this is a baseline figure, not an amount being offered.